PMID: 8986814Dec 24, 1996Paper

Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy

Proceedings of the National Academy of Sciences of the United States of America
E HananiaA B Deisseroth

Abstract

To formally test the hypothesis that the granulocyte/macrophage colony-forming unit (GM-CFU) cells can contribute to early hematopoietic reconstitution immediately after transplant, the frequency of genetically modified GM-CFU after retroviral vector transduction was measured by a quantitative in situ polymerase chain reaction (PCR), which is specific for the multidrug resistance-1 (MDR-1) vector, and by a quantitative GM-CFU methylcellulose plating assay. The results of this analysis showed no difference between the transduction frequency in the products of two different transduction protocols: "suspension transduction" and "stromal growth factor transduction." However, when an analysis of the frequency of cells positive for the retroviral MDR-1 vector posttransplantation was carried out, 0 of 10 patients transplanted with cells transduced by the suspension method were positive for the vector MDR-1 posttransplant, whereas 5 of 8 patients transplanted with the cells transduced by the stromal growth factor method were positive for the MDR-1 vector transcription unit by in situ or in solution PCR assay (a difference that is significant at the P = 0.0065 level by the Fisher exact test). These data suggest that only very small subs...Continue Reading

References

Aug 16, 1986·Lancet·L B ToC A Juttner
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianA B Deisseroth

❮ Previous
Next ❯

Citations

May 25, 2001·International Journal of Hematology·C M BollardM K Brenner
May 25, 2001·International Journal of Hematology·J Richter, S Karlsson
May 10, 2002·International Journal of Hematology·David W EmeryGeorge Stamatoyannopoulos
Mar 29, 2000·Critical Reviews in Oncology/hematology·D Rund, E Rachmilewitz
May 6, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·S LaufsS Fruehauf
Apr 18, 2000·Mutation Research·R B Roth, L D Samson
Aug 22, 2002·Nature Reviews. Cancer·Brian P Sorrentino
Oct 16, 1999·British Journal of Haematology·S QinA Bank
Apr 12, 2001·Journal of Internal Medicine·M K Brenner
Oct 25, 2000·Human Gene Therapy·D A Williams, F O Smith
Jan 25, 2000·Journal of Hematotherapy & Stem Cell Research·N Dalyot-HermanA Oppenheim
Dec 21, 2004·British Journal of Haematology·Amit C NathwaniDavid C Linch
Nov 5, 2005·Acta Haematologica·Pamela S Becker
Nov 5, 2005·Blood·Tobias NeffHans-Peter Kiem
Mar 7, 2006·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Shunji TakahashiYoshikazu Sugimoto
Jan 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·J M ZijlmansW E Fibbe
Aug 4, 1999·Molecular Medicine Today·C M VerfaillieR C Zhao
Sep 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·W PfutznerJ C Vogel
Feb 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Thomas LichtJohn R Melniczek
Oct 2, 2013·The Lancet Oncology·Malcolm K BrennerJuan F Vera
Dec 30, 1998·Leukemia & Lymphoma·E M NovelliC I Civin
Dec 4, 2003·Expert Opinion on Biological Therapy·S FruehaufS Laufs

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.